Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Realgar-Indigo naturalis formula
The First People's Hospital of Lianyungang
Acute Promyelocytic Leukemia
1 trial -
Recombinant 14-Valent Human Papillomavirus VaccineοΌInsect CellοΌ
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HPV InfectioN
1 trial -
Recombinant Human Albumin Injection
The First People's Hospital of Lianyungang
Hepatic Ascites
2 trials -
Recombinant Human Thrombopoietin (rhTPO)
The First People's Hospital of Lianyungang
Immune Thrombocytopenia
1 trial -
Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Respiratory Syncytial Virus (RSV)
1 trial -
Remdesivir
The First People's Hospital of Lianyungang
Covid19
1 trial -
Remifentanil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Analgesia
1 trial -
Remimazolam Besylate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Analgesia
1 trial -
Remimazolam Besylate
The First People's Hospital of Lianyungang
Critical Illness; Mechanical Ventilation; Shock
1 trial -
Remimazolam besylate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sedative
1 trial -
Rifaximin
The First People's Hospital of Lianyungang
Crohn Disease
1 trial -
Rifaximin
Hospital Authority, Hong Kong
Decompensated Cirrhosis
1 trial -
Riociguat
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chronic Thromboembolic Pulmonary Hypertension
1 trial -
Rituximab
The First People's Hospital of Lianyungang
Refractory Myasthenia Gravis
1 trial -
Rituximab
The First People's Hospital of Lianyungang
Diffuse Large B-cell Lymphoma
3 trials -
Rituximab
Hospital Authority, Hong Kong
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
1 trial -
Robotic Gastrectomy
The First People's Hospital of Lianyungang
Gastric Cancer (GC)
1 trial -
Romiplostim
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenia
1 trial -
Roux-en-Y anastomosis
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Cancer
1 trial -
S-1 therapy
The First People's Hospital of Lianyungang
Carcinoma, Non-Small-Cell Lung
1 trial -
SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19 Pneumonia
1 trial -
Sacubitril-Valsartan
Xiyuan Hospital of China Academy of Chinese Medical Sciences
STEMI
1 trial -
Saline (0.9%, sterile, for infusion)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pneumocystis Jiroveci Pneumonia
1 trial -
Sirolimus
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lupus Nephritis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources